Endobronchial valves for severe emphysema

Jorine E. Hartman*, Lowie E. G. W. Vanfleteren, Eva M. van Rikxoort, Karin Klooster, Dirk-Jan Slebost

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

22 Citations (Web of Science)

Abstract

The results of the randomised controlled trials investigating the bronchoscopic lung volume reduction treatment using endobronchial valves (EBV) are promising, and have led to their inclusion in treatment guidelines, US Food and Drug Administration approval and inclusion in routine care in an increasing number of countries. The one-way valve treatment has advanced and is now a regular treatment option. However, this new phase will lead to new challenges in terms of implementation. We believe that key issues in future research concern advanced patient selection, improved methods for target lobe selection, increased knowledge on the predictive risk of a pneumothorax, positioning of pulmonary rehabilitation in conjunction with the EBV treatment, the positioning of lung volume reduction surgery versus EBV treatment, and the long-term efficacy, adverse events, impact on exacerbations and hospitalisations, costs and survival. Hopefully, the increasing number of patients treated, the setup of (inter) national registries and future research efforts will further optimise all aspects of this treatment.

Original languageEnglish
Article number180121
Pages (from-to)1-7
Number of pages7
JournalEuropean Respiratory Review
Volume28
Issue number152
DOIs
Publication statusPublished - 30 Jun 2019

Keywords

  • LUNG-VOLUME-REDUCTION
  • TERM-FOLLOW-UP
  • THERAPY
  • PNEUMOTHORAX
  • SURVIVAL
  • TRIAL
  • PREDICTORS

Cite this